Title: Use of circulating tumor DNA (ctDNA) to monitor patients undergoing total neoadjuvant treatment (TNT) for locally advanced rectal adenocarcinoma (LARC). A growing body of research underscores ...
SECAUCUS, N.J. and NEW BRUNSWICK, N.J., Sept. 22, 2025 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (DGX) company, today announced a research collaboration with the Rutgers Cancer Institute ...
Quest Diagnostics DGX company, Haystack Oncology, recently announced a research collaboration with the Rutgers Cancer Institute, New Jersey's only National Cancer Institute-designated Comprehensive ...
Oncologists face a difficult decision after surgically removing a solid tumor. Some patients harbor residual cancer cells, known as minimal residual disease (MRD), and need additional therapy to avoid ...
A growing body of research underscores the value of ctDNA-based MRD testing to identify residual or recurring cancer in solid tumors. By detecting trace amounts of tumor-derived DNA in the bloodstream ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results